Subject
Biochemistry (medical),Clinical Biochemistry,Biochemistry,General Medicine
Reference50 articles.
1. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention;Gansevoort;Lancet.,2013
2. SHARP Investigators, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial;Baigent;Lancet.,2011
3. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;Circulation,2018
4. F. Mach, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, M.J. Chapman, G.G. De Backer, V. Delgado, B.A. Ference, I.M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T.R. Pedersen, G. Riccardi, D.J. Richter, M.S. Sabatine, M.R. Taskinen, L. Tokgozoglu, O. Wiklund, ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur. Heart J. 41 (2020) 111–188. https://doi.org/10.1093/eurheartj/ehz455.
5. Committee of Renal and Peripheral Arteries, Japan Atherosclerosis Society, Chronic kidney disease, dyslipidemia, and atherosclerosis;Shoji;J. Atheroscler. Thromb.,2012